CompletedNot Applicable

Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)

United Kingdom51 participantsStarted 2020-02-20

Plain-language summary

Manganese is a calcium analogue which actively enters viable cells with intact calcium-handling mechanisms and its uptake is evident by an increase in MRI-detectable T1 relaxivity of tissues. Mangafodipir is a novel manganese-based magnetic resonance imaging (MRI) contrast medium with unique biophysical properties that are ideal for application to cardiac imaging. Recent studies in man have demonstrated the utility of manganese-enhanced MRI (MEMRI) in assessing infarct size more accurately than with standard cardiac MRI protocols using gadolinium enhancement and have shown reduced myocardial manganese uptake in patients with cardiomyopathies suggesting abnormal calcium handling. Understanding the potential for myocardial recovery is key in guiding revascularisation therapies in ischaemic cardiomyopathy, in addition to novel therapies used in heart failure. Being able to monitor calcium handling and therefore myocardial function in different types of cardiomyopathies has the potential to guide management in these patients. The investigators here propose an investigational observational study of MEMRI to assess myocardial calcium handling in reversible causes of cardiomyopathy, namely ischaemic cardiomyopathy, myocarditis and takotsubo cardiomyopathy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: All subjects to be entered must: * ≥ 18 years of age * if female, be non-pregnant as evidenced by a urine pregnancy test or post-menopausal or surgically sterile * provide written informed consent after having received oral and written information about the study Additionally, cohort-specific inclusion criteria as follows: Cohort 1 • Healthy adult with no known pre-existing medical conditions Cohort 2 * Positive stress- akinesia/hypokinesis on pharmacological stress * Negative stress- no inducible regional wall motion abnormalities on pharmacological stress Cohort 3 * New left/right ventricular dysfunction; including regional wall motion abnormalities (RWMA's) * New abnormal ECG findings (conduction, atrio-ventricular block, ST/T wave changes) * Raised biomarkers (troponin, TnI) * Tissue characteristics on MRI (myocardial oedema and typical late gadolinium enhancement pattern) Cohort 4 * Normal/ Non-obstructive coronaries on angiography * Typical RWMA's based on echocardiography, MRI or left ventriculography Exclusion Criteria: * The following apply to all participants: * have a positive pregnancy test * women who are breast feeding * received an investigational drug or device within 30 days prior to administration of Mangafodipir * have a history of ongoing drug abuse or alcoholism * have a history of torsades or prolonged QT/QT corrected interval * high degree atrioventricular block (second or third degree) * atrial fibrillati…

What they're measuring

Myocardial T1 relaxation (ms)

Timeframe: 2 years

Manganese uptake (Ki)

Timeframe: 2 years

Trial details

NCT IDNCT04623788

SponsorUniversity of Edinburgh

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-06-02